Research & Discovery

The latest research news in genetics and genomics.

The company will use the funds to refine a nanoparticle-based immunoenrichment approach to simplifying sample separations up front of mass spec analysis.

The company also said that net income for the first half of 2017 rose 18 percent year over year to €101 million from €85.7 million.

The firm is looking for outside partners to tackle test commercialization as it begins to bring its second-generation colorectal cancer assay to market.

The companies will share bioinformatics and NGS expertise to speed the identification of diseases, accelerate drug discovery, and find "genomic shields."

NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.